DxS Ltd, the Manchester headquartered developer and manufacturer of companion diagnostic products, has been sold to genetic testing specialist Qiagen.
Under the deal quoted sample and assay technologies business, Qiagen has paid approximately US$95million (£58m) in cash with up to an additional US$35million (£21m) if specified commercial and other milestones are met.
DxS has developed a set of molecular diagnostic assays which allow physicians in oncology to predict patients’ responses to certain treatments in order to make cancer therapies more effective and safer.
“The acquisition of DxS is strategically a highly important transaction for QIAGEN,” said Peer M. Schatz, CEO of Qiagen. “It combines two leadership positions to create a very powerful leader in a transformational area of healthcare: personalized healthcare.”
Founder and CEO of DxS, Stephen Little, said that Qiagen was the ideal partner for DxS to globally roll out its assays, to take its partnerships to the next level and to take a leadership position in companion diagnostics.
He continued: “Unlike any other company, we believe that Qiagen addresses the broadest range of companion diagnostic options for pharmaceutical and large biotech companies – starting from an independent sales reach over broad technology, R&D and manufacturing capabilities up to expertise in regulatory affairs and access creation to physicians and laboratories.”
DxS’ senior management will join Qiagen in leading roles in the Company’s rapidly expanding personalized healthcare focus area, facilitating rapid integration and focus on the further expansion of this key segment.
For that purpose, Qiagen has indicated that it intends to establish DxS’ headquarters in Manchester as a Center of Excellence in Pharma Partnering.
Ends
To comment please login above.
Bookmark this: